Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania 17033, USA.
Alcohol Clin Exp Res. 2010 Jun;34(6):946-54. doi: 10.1111/j.1530-0277.2010.01169.x. Epub 2010 Apr 5.
The lack of reliable measures of alcohol intake is a major obstacle to the diagnosis, treatment, and research of alcohol abuse and alcoholism. Successful development of a biomarker that allows for accurate assessment of alcohol intake and drinking patterns would not only be a major advance in clinical care but also a valuable research tool. A number of advances have been made in testing the validity of proposed biomarkers as well as in identifying potential new biomarkers through systems biology approaches. This commentary will examine the definition of a biomarker of heavy drinking, the types of potential biomarkers, the steps in biomarker development, the current state of biomarker development, and critical obstacles for the field. The challenges in developing biomarkers for alcohol treatment and research are similar to those found in other fields. However, the alcohol research field must reach a competitive level of rigor and organization. We recommend that NIAAA consider taking a leadership role in organizing investigators in the field and providing a common set of clinical specimens for biomarker validation studies.
酒精摄入量缺乏可靠的测量手段是诊断、治疗和研究酒精滥用和酗酒的主要障碍。成功开发出一种生物标志物,能够准确评估酒精摄入量和饮酒模式,不仅将是临床护理的重大进展,也是有价值的研究工具。在通过系统生物学方法检验所提出的生物标志物的有效性以及确定潜在新生物标志物方面已经取得了一些进展。本评论将探讨大量饮酒生物标志物的定义、潜在生物标志物的类型、生物标志物开发的步骤、生物标志物开发的现状以及该领域的关键障碍。在开发酒精治疗和研究生物标志物方面的挑战与其他领域相似。然而,酒精研究领域必须达到严谨和组织的竞争水平。我们建议 NIAAA 考虑发挥领导作用,组织该领域的研究人员,并为生物标志物验证研究提供一组共同的临床标本。